US OptionsDetailed Quotes

AGEN241220P7000

Watchlist
  • 0.00
  • 0.000.00%
15min DelayClose Dec 11 09:30 ET
0.00High0.00Low
Intraday
  • 5D
  • Daily

No Data

News

Comments

    Jaguar8
    Jaguar8
    Dec 5 06:32
    NEWS
    $Agenus (AGEN.US)$
    Agenus Announces Strategic Realignment to Focus on Core Programs and Significantly Reduce Costs
    1 minute ago, 4:30 AM PST
    Via BusinessWire
    Agenus Inc., a leader in immuno-oncology, today announced further details of its strategic realignment aimed at streamlining operations, strengthening its financial position, and prioritizing the advancement of its most impactful programs as it prepares for 2025. Reductions are designed to reduce cash burn to $100 million in FY 2025. T...
    1
    Jaguar8
    Jaguar8
    Nov 27 07:15
    NEWS
    $Agenus (AGEN.US)$
    Agenus Secures $22 Million Mortgage and Announces Strategic Operational Realignment
    Agenus (NASDAQ: AGEN) has secured a $22 million mortgage backed by its Berkeley and Vacaville properties, providing $20 million in net proceeds.
    The two-year mortgage includes interest payable 50% in cash and 50% in common stock, at rates of 12% for Year 1 and 13% for Year 2.
    The company announced a Strategic Operational Realignment Plan focusing on botensilimab/balstilimab(BOT/BAL) in MSS...
    Jaguar8
    Jaguar8
    Nov 7 09:02
    NEWS
    $Agenus (AGEN.US)$
    Agenus to Present Compelling Data on Botensilimab and AGEN1721 at SITC 2024
    Agenus (NASDAQ: AGEN) will present new data on two promising immunotherapy candidates at the SITC 2024 Annual Meeting in Houston. The presentations will feature botensilimab, an Fc-enhanced anti-CTLA-4 antibody showing efficacy in treatment-resistant cancers, and AGEN1721, a first-in-class bifunctional antibody targeting FAP and TGFβ.
    Botensilimab enhances both innate and adaptive immunity, demonstr...
    1
    Jaguar8
    Jaguar8
    Sep 13 10:46
    NEWS
    $Agenus (AGEN.US)$
    Botensilimab/Balstilimab Clinical Responses in Refractory Sarcomas Presented at ESMO 2024
    Agenus Inc. (Nasdaq: AGEN) presented promising data at the ESMO Congress for their Phase 1 study of botensilimab (BOT) and balstilimab (BAL) combination in refractory sarcomas. Key findings include:
    - 23% overall response rate (ORR) in the full sarcoma cohort
    - 21.7 months median duration of response (DOR)
    - 69% 12-month overall survival (OS)
    - 39% ORR in angiosarcoma subtype
    - Managea...
Read more